Physician profile
Timothy Yoon
NPI 1568586675
$3,920.59
in general payments reported to CMS, 2019-2025
30 companies · $664 in 2025
The $664 reported for 2025 was more than what 83% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2021: $1,249 · 2022: $467 · 2023: $802 · 2024: $611 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $1,436.98 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $445.63 | 2024-2025 | Relistor |
| Abbvie INC. | $408.40 | 2022-2025 | Botox, Qulipta |
| Collegium Pharmaceutical, INC. | $299.00 | 2022-2025 | Belbuca, Xtampza |
| Averitas Pharma INC. | $180.74 | 2024-2025 | Qutenza |
| Nuvasive, INC. | $126.73 | 2019 | |
| Medtronic, INC. | $119.88 | 2023 | Intellis Adaptivestim, Absorbatack |
| Nevro Corp. | $79.19 | 2021-2024 | Senza |
| Pfizer INC. | $70.87 | 2023-2025 | |
| Grt US Holding, INC. | $69.14 | 2022 | |
| Lilly USA, LLC | $68.91 | 2021-2023 | Reyvow, Emgality |
| Biohaven Pharmaceuticals, INC. | $67.75 | 2021 | |
| Electronic Waveform Lab, INC. | $64.46 | 2023-2025 | |
| Amgen INC. | $64.04 | 2021-2024 | Krystexxa |
| Lundbeck LLC | $54.52 | 2022-2023 | Vyepti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $49.97 | 2023-2024 | Eterna |
| Scilex Pharmaceuticals INC. | $42.55 | 2022-2023 | Ztlido |
| Biohaven Pharmaceutical Holding Company Ltd. | $39.16 | 2022 | |
| Valinor Pharma, LLC | $35.82 | 2025 | Movantik |
| Boston Scientific Corporation | $34.62 | 2023 | Wavewriter Alpha Prime 16 |
| Saluda Medical Americas, INC. | $24.03 | 2025 | Evoke |
| Biodelivery Sciences International, INC. | $22.69 | 2021 | |
| Curonix LLC | $18.00 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Fidia Pharma USA INC. | $15.92 | 2023 | Hymovis, Triluron |
| Almatica Pharma LLC | $15.52 | 2022 | |
| Hikma Pharmaceuticals USA | $14.83 | 2023 | Kloxxado |
| Protega Pharmaceutials INC | $14.24 | 2024 | Roxybond |
| International Rehabilitative Sciences, INC | $13.09 | 2024 | Rs 4i Plus Sequential Stimulator |
| Redhill Biopharma INC. | $11.96 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.